EU regulatory agencies require that the dose must carry a warning about the risk of blood clots
Brussels Johnson & Johnson said on Tuesday that it will continue to resume production of its coronavirus vaccine in Europe. Previously, the European Union drug regulator said that a warning should be added to the product indicating that it may be related to a rare blood clot, but the benefits of injection are far greater than risk.
The European Medicines Agency said in a statement: “It is reported that the combination of blood clots and low platelets is very rare, and the overall benefits of the Covid-19 vaccine outweigh the risk of side effects.” The agency added that rare blood The clot is “very similar” to the blood clot associated with the AstraZeneca vaccine, and the agency has made similar recommendations.
Johnson & Johnson decided last week to postpone the launch of the vaccine in the 27 EU member states, after US regulators called for the suspension of the vaccine after worrying about possible serious side effects.
The EMA’s recommendations are not binding, but this is the first sign that Europe’s long-awaited single shot vaccine has been launched in Europe, which has already administered nearly 8 million people in the United States. The agency stated that the regulatory agencies of member states should decide how to proceed based on specific circumstances and vaccine availability.
In its statement, the agency emphasized the importance of possible side effects from treatment and issued guidelines for healthcare workers looking for rare bleeding disorders.